bullish
CureVac May Supply ~225M of Potential COVID-19 Vaccine Doses. A Big Win Over Moderna and BioNTech
324 Views21 Aug 2020 03:05
Today German coronavirus vaccine developer CureVac has concluded an Advanced Purchase Agreement (APA) to provide all EU Member States with up to...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Top Quartile
Andrei Zakharov
Covering IPOs, Healthcare and Technology Stocks
Price Chart(Sign Up to Access)
- CureVac Stock May Surge Another 20-30% Under New Bull-Case Scenario23 Nov 2020
- Success of Moderna’s COVID-19 Vaccine May Give a Boost to Stocks of Messenger RNA Companies13 Nov 2020
- Expecting First Results From Phase 1 Clinical Trials Of COVID-19 Vaccine In October28 Sep 2020
- CureVac May Supply ~225M of Potential COVID-19 Vaccine Doses. A Big Win Over Moderna and BioNTech21 Aug 2020
- How High Can CureVac Stock Go After Blockbuster IPO? We Update Bull Case Scenario to $80 Per Share17 Aug 2020
- CureVac IPO. Beating Rivals to Secure a COVID-19 Vaccine Based on MRNA Technology14 Aug 2020
x